Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19809987 | 1.00 | CYP2C19 (0.38) | CYP2C19TSHRCYP1A2ALDH1A1USP2 | |
| SCHEMBL3764731 | 1.00 | CYP2C19 (0.38) | CYP2C19TSHRCYP1A2ALDH1A1USP2 | |
| SCHEMBL5549643 | 0.84 | — | — | |
| SCHEMBL13082839 | 0.83 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL12393389 | 0.83 | NPSR1 (0.33) | CYP2C19TSHR | |
| SCHEMBL1734564 | 0.83 | KARS1 (0.32) | — | |
| SCHEMBL13059598 | 0.83 | KARS1 (0.32) | — | |
| SCHEMBL5553350 | 0.82 | — | — | |
| SCHEMBL5553336 | 0.80 | GAA (0.40) | ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL7127146 | 0.80 | GAA (0.40) | ALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285546-B2 | Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents | STRAGEN PHARMA S.A. (CH) | 2007-10-23 | — | — | US | disclosed |
| EP-1328527-B1 | CEPHALOTAXANES, THEIR METHOD OF PREPARATION AND THEIR USE IN TREATMENT OF CANCERS, LEUKEMIAS, PARASITES INCLUDING THOSE RESISTANT TO USUAL CHEMOTHERAPEUTIC AGENTS AND AS REVERSAL AGENTS | STRAGEN PHARMA SA (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006064-A1 | Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents | IVAX International GmbH (CH) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006064-A1 | Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents | MCL1, CYCS, CYC1 | CYP2C19 1063/4885TSHR 2195/4885CYP1A2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.